BCAT1 and central nervous system cancer: Additionally, U87-CHIP cells treated with temozolomide exhibited a higher ratio of apoptotic cells in comparison to wild-type U87 cells and U87-CHIP/BCAT1K360R cells (Fig. 9B, C), indicating that CHIP-mediated BCAT1 degradation promoted temozolomide sensitivity in glioma cells.